Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of sarilumab vs tocilizumab in TNF inadequate responder rheumatoid arthritis
2012-003536-23Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Sarilumab arm with Tocilizumab (RoActemra) arm (2 arms). Primary endpoint: Safety and tolerability. Started Jan 2013; status: completed.
02
Drugs
sarilumabtocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-003536-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003536-23.